Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belantamab Mafodotin in High-Risk Smoldering Multiple Myeloma (BELLA)
NCT05055063Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2022
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of belantamab mafodotin in smoldering multiple myeloma (SMM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Recommended Phase 2 Dose or Maximum Tolerated Dose at 1 year. Started May 2022; status: recruiting.
02
Drugs
belantamab mafodotin
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT05055063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05055063.